ULTI.OL
Price:
$2.05
Market Cap:
$70.53M
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Industry
Biotechnology
IPO Date
2019-06-03
Stock Exchange
OSL
Ticker
ULTI.OL
According to Ultimovacs ASA’s latest financial reports and current stock price. The company's current Current Ratio is 3.62. This represents a change of -50.79% compared to the average of 7.35 of the last 4 quarters.
The mean historical Current Ratio of Ultimovacs ASA over the last ten years is 10.56. The current 3.62 Current Ratio has changed 3.32% with respect to the historical average. Over the past ten years (40 quarters), ULTI.OL's Current Ratio was at its highest in in the September 2019 quarter at 51.98. The Current Ratio was at its lowest in in the March 2017 quarter at 0.
Average
10.56
Median
10.46
Minimum
3.62
Maximum
20.12
Discovering the peaks and valleys of Ultimovacs ASA Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 262.08%
Maximum Annual Current Ratio = 20.12
Minimum Annual Increase = -54.72%
Minimum Annual Current Ratio = 3.62
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 3.62 | -25.43% |
| 2023 | 4.85 | -48.89% |
| 2022 | 9.49 | -17.06% |
| 2021 | 11.44 | -30.07% |
| 2020 | 16.36 | -18.70% |
| 2019 | 20.12 | 213.67% |
| 2018 | 6.41 | -54.72% |
| 2017 | 14.17 | -5.50% |
| 2016 | 14.99 | 262.08% |
The current Current Ratio of Ultimovacs ASA (ULTI.OL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
5.98
5-year avg
9.15
10-year avg
10.56
Ultimovacs ASA’s Current Ratio is less than BerGenBio ASA (4.39), less than Nordic Nanovector ASA (0), greater than Targovax ASA (2.33), less than Nykode Therapeutics AS (15.21), greater than PCI Biotech Holding ASA (2.94),
| Company | Current Ratio | Market cap |
|---|---|---|
| 4.39 | $45.74M | |
| 0 | $451.20M | |
| 2.33 | $123.47M | |
| 15.21 | $812.45M | |
| 2.94 | $10.41M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ultimovacs ASA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ultimovacs ASA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Ultimovacs ASA's Current Ratio?
How is the Current Ratio calculated for Ultimovacs ASA (ULTI.OL)?
What is the highest Current Ratio for Ultimovacs ASA (ULTI.OL)?
What is the 3-year average Current Ratio for Ultimovacs ASA (ULTI.OL)?
What is the 5-year average Current Ratio for Ultimovacs ASA (ULTI.OL)?
How does the current Current Ratio for Ultimovacs ASA (ULTI.OL) compare to its historical average?